

## **DNA Diagnostics Market - Global Outlook & Forecast 2025-2030**

Market Report | 2025-04-16 | 429 pages | Arizton Advisory & Intelligence

### **AVAILABLE LICENSES:**

- Single User License \$4799.00
- Team License \$4999.00
- Enterprisewide \$5999.00

### **Report description:**

The global DNA diagnostics market is expected to grow at a CAGR of 8.81% from 2024 to 2030.

### **MARKET TRENDS & DRIVERS**

#### **Emergence of Liquid Biopsy**

The development of liquid biopsy is an innovative jump in DNA diagnostics. By activating non-invasive, accurate, real-time analysis of genetic material, liquid biopsies open new limitations to the detection of disease, personalized medicine, and treatment surveillance. With the continued advances and growth of various applications, this technology is posing an unprecedented opportunity for growth and innovation in the global DNA diagnostics market.

#### **Increase in Direct-to-Consumer (DTC) Testing**

The increase in DTC testing is revolutionizing the global DNA diagnostics market by making genetic insights more accessible and personalized. Rising consumer interest in ancestry and health-related insights is driving this trend, offering significant growth opportunities for companies. As technological advancements and strategic partnerships continue to shape the industry, the future of DNA diagnostics lies in innovation, personalization, and ethical practices.

#### **Transition from Classical to Smart Bioinformatics**

The transition from classical to smart bioinformatics, coupled with the rising integration of AI, is reshaping the global DNA diagnostics market. This paradigm shift enhances the accuracy, speed, and accessibility of genetic testing, unlocking immense potential for innovation in personalized medicine, cancer diagnostics, and infectious disease management. By embracing these advancements, the global DNA diagnostics market is poised for sustained growth, addressing the evolving healthcare needs of a diverse global population.

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

## Advancements in Genomics and Personalized Medicine

Advancements in genomics and personalized medicine are reshaping the global DNA diagnostics market, driving innovation, and creating new opportunities for healthcare providers, technology developers, and patients. By leveraging these advancements, the market is positioned to address critical healthcare challenges and improve patient outcomes, heralding a new age of precision diagnostics and treatment.

## Increasing Prevalence of Genetic and Chronic Disorders

The increasing prevalence of genetic and chronic disorders has emerged as a key driver of the global DNA diagnostics market. Advances in molecular technologies, the growing adoption of precision medicine, and supportive government initiatives have created a robust foundation for the market's expansion. The future of DNA diagnostics holds immense potential for transforming healthcare, offering innovative solutions for early diagnosis, personalized treatment, and improved patient outcomes. As the market continues to evolve, it will play a pivotal role in addressing the global healthcare burden of genetic and chronic diseases.

## Technological Advancements in DNA Sequencing

Technological advancements in DNA sequencing are undeniably the driving force behind the rapid growth of the global DNA diagnostics market. By enabling highly accurate and efficient genetic analysis, these innovations are transforming healthcare delivery and paving the way for personalized medicine. As DNA sequencing technologies continue to evolve, they hold immense potential to reshape diagnostics, improve patient outcomes, and expand the horizons of genomic medicine on a global scale.

## Expanding Applications of DNA Diagnostics

The expanding applications of DNA diagnostics across disease detection, personalized medicine, reproductive health, consumer genomics, and drug development are driving the growth of the global DNA diagnostics market. Advances in genomics, combined with technological innovations, are transforming healthcare by making diagnostics more precise, accessible, and impactful. As the scope of DNA diagnostics continues to widen, it will play a pivotal role in shaping the future of medicine and public health.

## Rising Awareness of Early Disease Detection

The rising awareness of early disease detection is a crucial factor driving the global DNA diagnostics market. With an increasing emphasis on preventive healthcare, advancements in genetic testing technologies, and the growing need for personalized medicine, DNA diagnostics are becoming indispensable tools for early disease detection. The benefits of early diagnosis, including improved patient outcomes and more efficient healthcare systems, continue to fuel the demand for DNA diagnostics.

## SEGMENTATION INSIGHTS

### INSIGHTS BY PRODUCT TYPE

The global DNA diagnostics market is segmented based on product type, including consumables, instruments & software, and services. The consumables segment holds the most significant market share in 2024. Consumables are a key factor in the DNA diagnostics market, leading to the success and efficiency of genetic testing technologies. From reagents and PCR consumables to sequencing kits and sample preparation tools, these products are essential to the functioning of diagnostic tests across numerous applications. The increasing demand for genetic testing, personalized medicine, and precision healthcare, combined with advances in genomic technologies, is causing the market for DNA diagnostics consumables. Furthermore, instruments and

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

software are essential to the DNA diagnostics market, enabling innovation and improving patient outcomes through precise and efficient diagnostic procedures. While challenges such as regulatory compliance and cost remain, ongoing advancements in automation, AI, and cloud computing are unlocking new opportunities.

#### Segmentation by Product Type

- Consumables
- Instruments & Software
- Services

#### INSIGHTS BY TECHNOLOGY

The increasing prevalence of infectious diseases like COVID-19, tuberculosis, and HIV, along with its cost-effectiveness and high sensitivity, continues to drive the adoption of PCR-based DNA diagnostics. Such factors have contributed to the growth of the Polymerase Chain Reaction (PCR) segment in the global DNA diagnostics market, enabling it to hold the most significant segmental share. Advancements in real-time PCR (qPCR) and digital PCR (dPCR) further enhance accuracy and efficiency. The rising demand for Next-Generation Sequencing (NGS) in precision medicine, oncology, and rare disease diagnosis is a major growth driver. The decreasing cost of sequencing and improvements in bioinformatics tools are also expanding its applications in genetic testing.

The growing need for cancer diagnostics and cytogenetic analysis is fueling the demand for ISH techniques, including Fluorescence In Situ Hybridization (FISH), which enables detailed chromosomal analysis for disease detection and prognosis. The expanding applications of microarrays in gene expression profiling, pharmacogenomics, and prenatal screening contribute to market growth. Its high-throughput nature allows for large-scale genetic analysis, making it valuable for clinical and research applications.

#### Segmentation by Technology

- Polymerase Chain Reaction (PCR)
- Sequencing
- In-Situ Hybridization (ISH)
- Microarray
- DNA Fingerprinting
- Others

#### INSIGHTS BY SAMPLE TYPE

The global DNA diagnostics market by sample type is segmented into blood, serum & plasma, saliva, and others. Blood, serum, and plasma remain dominant due to their high reliability, especially in oncology and prenatal testing, while saliva-based tests are fueling the growth of at-home and pharmacogenomics markets. In 2024, the blood, serum & plasma segment held the most significant market share. The market for DNA diagnostics using these sample types is growing rapidly, driven by innovations in sequencing, PCR, and automated processing technologies. Future advancements in molecular diagnostics, coupled with improved regulatory frameworks, will further enhance the adoption of these sample types in clinical and research settings. However, alternative sample types like buccal swabs, tissue, urine, and hair are driving specialized applications in cancer, forensic, and genetic screening, ensuring continued expansion of the global DNA diagnostics market. The choice of sample type in DNA diagnostics is influenced by factors such as ease of collection, accuracy, and specific clinical applications.

#### Segmentation by Sample Type

- Blood, Serum & Plasma
- Saliva

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

-[]Others

## INSIGHTS BY APPLICATION

The global DNA diagnostics market by application is segmented into cancer, infectious diseases, prenatal testing, newborn genetic screening, forensics, and others. The cancer segment dominated the global market share and is poised for significant growth during the forecast period. DNA diagnostics is transforming cancer care by enabling early detection, guiding targeted therapies, assessing hereditary risk, and monitoring treatment response. Despite challenges such as cost, data interpretation, and ethical concerns, the market is poised for significant growth. Continued advancements in NGS, liquid biopsy, and AI-driven genomic analysis will drive further innovation in cancer diagnostics, ultimately improving patient outcomes worldwide. Furthermore, DNA diagnostics is transforming infectious disease management by providing highly accurate, rapid, and cost-effective molecular testing solutions. As next-generation sequencing, automation, and AI-driven analytics continue to advance, the global DNA diagnostics market will expand further. Companies investing in affordable, rapid, and accessible molecular diagnostics will play a critical role in the future of infectious disease control and global health security.

### Segmentation by Application

- []Cancer
- []Infectious Diseases
- []Prenatal Testing
- []Newborn Genetic Screening
- []Forensics
- []Others

## INSIGHTS BY END-USER

The global DNA diagnostics market by end-user is segmented into diagnostic centers, hospitals & clinics, and others. Diagnostic centers will dominate the global market in 2024, capturing the largest share and driving significant growth in the market. Diagnostic centers are benefiting from technological advancements and outsourcing trends, hospitals & clinics are integrating genomics into personalized medicine, and research institutions, forensic labs, Pharma & biotech companies, CROs & CDMOs are expanding applications in drug discovery and forensic science. With continuous innovation, regulatory support, and increasing awareness, DNA diagnostics is set to play a crucial role in the future of healthcare and biotechnology. Each End-user segment is significantly contributing to the growth of the global DNA diagnostics market.

### Segmentation by End-User

- []Diagnostic Centers
- []Hospitals & Clinics
- []Others

## GEOGRAPHICAL ANALYSIS

North America, led by the U.S. and Canada, holds the largest share of the global DNA diagnostics market, driven by the high adoption of genetic testing, precision medicine, and NGS-based diagnostics. The rapid development of next-generation sequencing (NGS), CRISPR-based technologies, and polymerase chain reaction (PCR) has made DNA diagnostics more accurate, faster, and cost-effective. The growth of precision medicine, which tailors medical treatment to individual genetic profiles, has further fueled the demand for genetic testing. Furthermore, the U.S. dominates the global DNA diagnostics market due to the strong presence of leading industry players and government funding for genomics (e.g., NIH's All of Us Research Program). Europe is the second-largest DNA diagnostics market, led by Germany, the UK, France, Italy, and Spain. Growth is fueled by strong

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

regulatory support, government-backed genomics programs, and high adoption of molecular diagnostics. The UK's Genomics England Initiative and Germany's National Genome Initiative are driving advancements in DNA-based diagnostics. Furthermore, APAC is the fastest-growing region in the global DNA diagnostics market due to rising healthcare investments, growing awareness of genetic diseases, and expanding diagnostic infrastructure. China, Japan, and India are major contributors, with initiatives like national genome projects boosting market growth.

The DNA diagnostics market in Latin America is experiencing significant growth, driven by increasing healthcare needs, advancements in genetic technologies, and rising awareness about the potential of genetic testing in disease diagnosis and prevention. Latin America, with its diverse population and evolving healthcare infrastructure, is emerging as a key region for the adoption of DNA diagnostics. Brazil and Mexico lead the region with expanding healthcare facilities. Further, the Middle East & Africa region is in the early stages of DNA diagnostics adoption, but growth is driven by government initiatives in Gulf countries (UAE, Saudi Arabia) to develop genomic research programs. While the region presents a complex landscape with diverse healthcare systems, varying levels of access to technology, and different regulatory frameworks, the demand for DNA diagnostics services is expected to continue expanding.

-□North America

o□The U.S.

o□Canada

-□Europe

o□Germany

o□The U.K.

o□France

o□Italy

o□Spain

o□Switzerland

o□Netherlands

-□APAC

o□China

o□Japan

o□India

o□South Korea

o□Australia

-□Latin America

o□Brazil

o□Mexico

o□Argentina

o□Colombia

-□Middle East & Africa

o□Turkey

o□South Africa

o□Saudi Arabia

o□UAE

## COMPETITIVE LANDSCAPE

The global DNA diagnostics market is experiencing rapid growth, driven by advancements in molecular biology, next-generation sequencing (NGS), polymerase chain reaction (PCR) technologies, and bioinformatics. The increasing prevalence of genetic disorders, infectious diseases, and cancers, coupled with the rising adoption of precision medicine, has fueled demand for

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

DNA-based diagnostic solutions. This market is highly competitive, with established biotechnology and life sciences companies striving for technological superiority, cost-effectiveness, and regulatory approvals. The DNA diagnostics market is dominated by global biotechnology and molecular diagnostics companies specializing in genetic sequencing, PCR, microarrays, and companion diagnostics. Furthermore, companies are focusing on clinical genomics, oncology, reproductive health, and infectious diseases to increase the adoption of DNA-based diagnostics. For instance, Illumina's NGS technology is expanding into cancer diagnostics, prenatal screening, and rare disease detection.

The global DNA diagnostics market is highly competitive, with major players investing in NGS, PCR, liquid biopsy, and AI-driven bioinformatics to maintain leadership. Companies like Abbott, F. Hoffmann-La Roche, Illumina, QIAGEN, and Thermo Fisher Scientific are driving innovation, while emerging players and startups are disrupting traditional models. For instance, Abbott is a major player in molecular diagnostics, focusing on infectious disease testing, oncology, and genetic disorders. The company has strong expertise in real-time PCR, point-of-care (POC) diagnostics, and molecular diagnostic platforms, making DNA testing more accessible and automated.

#### Key Company Profiles

- [ ] Abbott
- [ ] F. Hoffmann La-Roche
- [ ] Illumina
- [ ] QIAGEN
- [ ] Thermo Fisher Scientific

#### Other Prominent Vendors

- [ ] 23andMe
- [ ] 24Genetics
- [ ] Agilent Technologies
- [ ] Ancestry
- [ ] Beyond Nutrition Health and Wellness Services DMCC
- [ ] BillionToOne
- [ ] CircleDNA
- [ ] Danaher
- [ ] EverlyWell
- [ ] GE Healthcare
- [ ] GeneDx
- [ ] Genetrack India
- [ ] Helix
- [ ] Igenomix
- [ ] Mainz Biomed N.V.
- [ ] Mapmygenome
- [ ] Merck KgaA
- [ ] myDNA Life Australia
- [ ] MyHeritage
- [ ] Natera
- [ ] tellmeGen
- [ ] Vitagen-X Precision Nutrition

#### KEY QUESTIONS ANSWERED:

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

1. How big is the global DNA diagnostics market?
2. What is the growth rate of the global DNA diagnostics market?
3. Which region dominates the global DNA diagnostics market share?
4. What are the significant trends in the DNA diagnostics industry?
5. Who are the key players in the global DNA diagnostics market?

## **Table of Contents:**

1. SCOPE & COVERAGE
  - 1.1. MARKET DEFINITION
    - 1.1.1. INCLUSIONS
    - 1.1.2. EXCLUSIONS
    - 1.1.3. MARKET ESTIMATION CAVEATS
  - 1.2. MARKET SEGMENT COVERAGE & DEFINITION
    - 1.2.1. PRODUCT TYPE
    - 1.2.2. TECHNOLOGY
    - 1.2.3. SAMPLE TYPE
    - 1.2.4. APPLICATION
    - 1.2.5. END-USER
    - 1.2.6. REGIONS & COUNTRIES COVERED
  - 1.3. MARKET DERIVATION
- BASE YEAR
2. PREMIUM INSIGHTS
  - 2.1. OPPORTUNITY POCKETS
  - 2.2. OVERVIEW
3. MARKET AT A GLANCE
4. INTRODUCTION
  - 4.1. OVERVIEW
5. MARKET OPPORTUNITIES & TRENDS
  - 5.1. EMERGENCE OF LIQUID BIOPSY
  - 5.2. INCREASE IN DIRECT-TO-CONSUMER (DTC) TESTING
  - 5.3. TRANSITION FROM CLASSICAL TO SMART BIOINFORMATICS
  - 5.4. ADVANCEMENTS IN GENOMICS AND PERSONALIZED MEDICINE
6. MARKET GROWTH ENABLERS
  - 6.1. INCREASING PREVALENCE OF GENETIC AND CHRONIC DISORDERS
  - 6.2. TECHNOLOGICAL ADVANCEMENTS IN DNA SEQUENCING
  - 6.3. EXPANDING APPLICATIONS OF DNA DIAGNOSTICS
  - 6.4. RISING AWARENESS OF EARLY DISEASE DETECTION
7. MARKET RESTRAINTS
  - 7.1. AVAILABILITY OF ALTERNATE DISEASE DIAGNOSTIC & DETECTION METHODS
  - 7.2. ETHICAL AND PRIVACY CONCERNS
  - 7.3. COMPLEX REGULATORY FRAMEWORKS
8. MARKET LANDSCAPE
  - 8.1. MARKET OVERVIEW
  - 8.2. MARKET SIZE & FORECAST
  - 8.3. FIVE FORCES ANALYSIS
    - 8.3.1. THREAT OF NEW ENTRANTS

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 8.3.2. □BARGAINING POWER OF SUPPLIERS
- 8.3.3. □BARGAINING POWER OF BUYERS
- 8.3.4. □THREAT OF SUBSTITUTES
- 8.3.5. □COMPETITIVE RIVALRY
- 9. □PRODUCT TYPE
- 9.1. □MARKET SNAPSHOT & GROWTH ENGINE
- 9.2. □MARKET OVERVIEW
- 9.3. □CONSUMABLES
- 9.3.1. □MARKET OVERVIEW
- 9.3.2. □MARKET SIZE & FORECAST
- 9.3.3. □MARKET BY GEOGRAPHY
- 9.4. □INSTRUMENTS & SOFTWARE
- 9.4.1. □MARKET OVERVIEW
- 9.4.2. □MARKET SIZE & FORECAST
- 9.4.3. □MARKET BY GEOGRAPHY
- 9.5. □SERVICES
- 9.5.1. □MARKET OVERVIEW
- 9.5.2. □MARKET SIZE & FORECAST
- 9.5.3. □MARKET BY GEOGRAPHY
- 10. □TECHNOLOGY
- 10.1. □MARKET SNAPSHOT & GROWTH ENGINE
- 10.2. □MARKET OVERVIEW
- 10.3. □POLYMERASE CHAIN REACTION (PCR)
- 10.3.1. □MARKET OVERVIEW
- 10.3.2. □MARKET SIZE & FORECAST
- 10.3.3. □MARKET BY GEOGRAPHY
- 10.4. □SEQUENCING
- 10.4.1. □MARKET OVERVIEW
- 10.4.2. □MARKET SIZE & FORECAST
- 10.4.3. □MARKET BY GEOGRAPHY
- 10.5. □IN-SITU HYBRIDIZATION (ISH)
- 10.5.1. □MARKET OVERVIEW
- 10.5.2. □MARKET SIZE & FORECAST
- 10.5.3. □MARKET BY GEOGRAPHY
- 10.6. □MICROARRAY
- 10.6.1. □MARKET OVERVIEW
- 10.6.2. □MARKET SIZE & FORECAST
- 10.6.3. □MARKET BY GEOGRAPHY
- 10.7. □DNA FINGERPRINTING
- 10.7.1. □MARKET OVERVIEW
- 10.7.2. □MARKET SIZE & FORECAST
- 10.7.3. □MARKET BY GEOGRAPHY
- 10.8. □OTHERS
- 10.8.1. □MARKET OVERVIEW
- 10.8.2. □MARKET SIZE & FORECAST
- 10.8.3. □MARKET BY GEOGRAPHY
- 11. □SAMPLE TYPE

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 11.1. □ MARKET SNAPSHOT & GROWTH ENGINE
- 11.2. □ MARKET OVERVIEW
- 11.3. □ BLOOD, SERUM & PLASMA
  - 11.3.1. □ MARKET OVERVIEW
  - 11.3.2. □ MARKET SIZE & FORECAST
  - 11.3.3. □ MARKET BY GEOGRAPHY
- 11.4. □ SALIVA
  - 11.4.1. □ MARKET OVERVIEW
  - 11.4.2. □ MARKET SIZE & FORECAST
  - 11.4.3. □ MARKET BY GEOGRAPHY
- 11.5. □ OTHERS
  - 11.5.1. □ MARKET OVERVIEW
  - 11.5.2. □ MARKET SIZE & FORECAST
  - 11.5.3. □ MARKET BY GEOGRAPHY
- 12. □ APPLICATION
  - 12.1. □ MARKET SNAPSHOT & GROWTH ENGINE
  - 12.2. □ MARKET OVERVIEW
  - 12.3. □ CANCER
    - 12.3.1. □ MARKET OVERVIEW
    - 12.3.2. □ MARKET SIZE & FORECAST
    - 12.3.3. □ MARKET BY GEOGRAPHY
  - 12.4. □ INFECTIOUS DISEASES
    - 12.4.1. □ MARKET OVERVIEW
    - 12.4.2. □ MARKET SIZE & FORECAST
    - 12.4.3. □ MARKET BY GEOGRAPHY
  - 12.5. □ PRENATAL TESTING
    - 12.5.1. □ MARKET OVERVIEW
    - 12.5.2. □ MARKET SIZE & FORECAST
    - 12.5.3. □ MARKET BY GEOGRAPHY
  - 12.6. □ FORENSICS
    - 12.6.1. □ MARKET OVERVIEW
    - 12.6.2. □ MARKET SIZE & FORECAST
    - 12.6.3. □ MARKET BY GEOGRAPHY
  - 12.7. □ NEWBORN GENETIC SCREENING
    - 12.7.1. □ MARKET OVERVIEW
    - 12.7.2. □ MARKET SIZE & FORECAST
    - 12.7.3. □ MARKET BY GEOGRAPHY
  - 12.8. □ OTHERS
    - 12.8.1. □ MARKET OVERVIEW
    - 12.8.2. □ MARKET SIZE & FORECAST
    - 12.8.3. □ MARKET BY GEOGRAPHY
- 13. □ END USER
  - 13.1. □ MARKET SNAPSHOT & GROWTH ENGINE
  - 13.2. □ MARKET OVERVIEW
  - 13.3. □ DIAGNOSTIC CENTERS
    - 13.3.1. □ MARKET OVERVIEW
    - 13.3.2. □ MARKET SIZE & FORECAST

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 13.3.3. □ MARKET BY GEOGRAPHY
- 13.4. □ HOSPITALS & CLINICS
  - 13.4.1. □ MARKET OVERVIEW
  - 13.4.2. □ MARKET SIZE & FORECAST
  - 13.4.3. □ MARKET BY GEOGRAPHY
- 13.5. □ OTHERS
  - 13.5.1. □ MARKET OVERVIEW
  - 13.5.2. □ MARKET SIZE & FORECAST
  - 13.5.3. □ MARKET BY GEOGRAPHY
- 14. □ GEOGRAPHY
  - 14.1. □ MARKET SNAPSHOT & GROWTH ENGINE
  - 14.2. □ GEOGRAPHIC OVERVIEW
- 15. □ NORTH AMERICA
  - 15.1. □ MARKET OVERVIEW
  - 15.2. □ MARKET SIZE & FORECAST
    - 15.2.1. □ PRODUCT TYPE
    - 15.2.2. □ TECHNOLOGY
    - 15.2.3. □ SAMPLE TYPE
    - 15.2.4. □ APPLICATION
    - 15.2.5. □ END-USER
  - 15.3. □ KEY COUNTRIES
    - 15.3.1. □ US: MARKET SIZE & FORECAST
    - 15.3.2. □ CANADA: MARKET SIZE & FORECAST
- 16. □ EUROPE
  - 16.1. □ MARKET OVERVIEW
  - 16.2. □ MARKET SIZE & FORECAST
    - 16.2.1. □ PRODUCT TYPE
    - 16.2.2. □ TECHNOLOGY
    - 16.2.3. □ SAMPLE TYPE
    - 16.2.4. □ APPLICATION
    - 16.2.5. □ END USER
  - 16.3. □ KEY COUNTRIES
    - 16.3.1. □ GERMANY: MARKET SIZE & FORECAST
    - 16.3.2. □ UK: MARKET SIZE & FORECAST
    - 16.3.3. □ FRANCE: MARKET SIZE & FORECAST
    - 16.3.4. □ ITALY: MARKET SIZE & FORECAST
    - 16.3.5. □ SPAIN: MARKET SIZE & FORECAST
    - 16.3.6. □ SWITZERLAND: MARKET SIZE & FORECAST
    - 16.3.7. □ NETHERLANDS: MARKET SIZE & FORECAST
- 17. □ APAC
  - 17.1. □ MARKET OVERVIEW
  - 17.2. □ MARKET SIZE & FORECAST
    - 17.2.1. □ PRODUCT TYPE
    - 17.2.2. □ TECHNOLOGY
    - 17.2.3. □ SAMPLE TYPE
    - 17.2.4. □ APPLICATION
    - 17.2.5. □ END USER

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 17.3. □KEY COUNTRIES
  - 17.3.1. □CHINA: MARKET SIZE & FORECAST
  - 17.3.2. □JAPAN: MARKET SIZE & FORECAST
  - 17.3.3. □INDIA: MARKET SIZE & FORECAST
  - 17.3.4. □SOUTH KOREA: MARKET SIZE & FORECAST
  - 17.3.5. □AUSTRALIA: MARKET SIZE & FORECAST
- 18. □LATIN AMERICA
  - 18.1. □MARKET OVERVIEW
  - 18.2. □MARKET SIZE & FORECAST
    - 18.2.1. □PRODUCT TYPE
    - 18.2.2. □TECHNOLOGY
    - 18.2.3. □SAMPLE TYPE
    - 18.2.4. □APPLICATION
    - 18.2.5. □END USER
  - 18.3. □KEY COUNTRIES
    - 18.3.1. □BRAZIL: MARKET SIZE & FORECAST
    - 18.3.2. □MEXICO: MARKET SIZE & FORECAST
    - 18.3.3. □ARGENTINA: MARKET SIZE & FORECAST
    - 18.3.4. □COLOMBIA: MARKET SIZE & FORECAST
- 19. □MIDDLE EAST & AFRICA
  - 19.1. □MARKET OVERVIEW
  - 19.2. □MARKET SIZE & FORECAST
    - 19.2.1. □PRODUCT TYPE
    - 19.2.2. □TECHNOLOGY
    - 19.2.3. □SAMPLE TYPE
    - 19.2.4. □APPLICATION
    - 19.2.5. □END USER
  - 19.3. □KEY COUNTRIES
    - 19.3.1. □TURKEY: MARKET SIZE & FORECAST
    - 19.3.2. □SOUTH AFRICA: MARKET SIZE & FORECAST
    - 19.3.3. □SAUDI ARABIA: MARKET SIZE & FORECAST
    - 19.3.4. □UAE: MARKET SIZE & FORECAST
- 20. □COMPETITIVE LANDSCAPE
  - 20.1. □COMPETITION OVERVIEW
  - 20.2. □MARKET SHARE ANALYSIS
    - 20.2.1. □ABBOTT
    - 20.2.2. □F. HOFFMANN-LA ROCHE
    - 20.2.3. □ILLUMINA
    - 20.2.4. □QAIGEN
    - 20.2.5. □THERMO FISHER SCIENTIFIC
- 21. □KEY COMPANY PROFILES
  - 21.1. □ABBOTT
    - 21.1.1. □BUSINESS OVERVIEW
    - 21.1.2. □PRODUCT OFFERINGS
    - 21.1.3. □KEY STRATEGIES
    - 21.1.4. □KEY STRENGTHS
    - 21.1.5. □KEY OPPORTUNITIES

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 21.2. F. HOFFMANN-LA ROCHE
  - 21.2.1. BUSINESS OVERVIEW
  - 21.2.2. PRODUCT OFFERINGS
  - 21.2.3. KEY STRATEGIES
  - 21.2.4. KEY STRENGTHS
  - 21.2.5. KEY OPPORTUNITIES
- 21.3. ILLUMINA
  - 21.3.1. BUSINESS OVERVIEW
  - 21.3.2. PRODUCT OFFERINGS
  - 21.3.3. KEY STRATEGIES
  - 21.3.4. KEY STRENGTHS
  - 21.3.5. KEY OPPORTUNITIES
- 21.4. QAIGEN
  - 21.4.1. BUSINESS OVERVIEW
  - 21.4.2. PRODUCT OFFERINGS
  - 21.4.3. KEY STRATEGIES
  - 21.4.4. KEY STRENGTHS
  - 21.4.5. KEY OPPORTUNITIES
- 21.5. THERMO FISHER SCIENTIFIC
  - 21.5.1. BUSINESS OVERVIEW
  - 21.5.2. PRODUCT OFFERINGS
  - 21.5.3. KEY STRATEGIES
  - 21.5.4. KEY STRENGTHS
  - 21.5.5. KEY OPPORTUNITIES
- 22. OTHER PROMINENT VENDORS
  - 22.1. 23ANDME
    - 22.1.1. BUSINESS OVERVIEW
    - 22.1.2. PRODUCT OFFERINGS
  - 22.2. 24GENETICS
    - 22.2.1. BUSINESS OVERVIEW
    - 22.2.2. PRODUCT OFFERINGS
  - 22.3. AGILENT TECHNOLOGIES
    - 22.3.1. BUSINESS OVERVIEW
    - 22.3.2. PRODUCT OFFERINGS
  - 22.4. ANCESTRY
    - 22.4.1. BUSINESS OVERVIEW
    - 22.4.2. PRODUCT OFFERINGS
  - 22.5. BEYOND NUTRITION HEALTH AND WELLNESS SERVICES DMCC
    - 22.5.1. BUSINESS OVERVIEW
    - 22.5.2. PRODUCT OFFERINGS
  - 22.6. BILLIONTOONE
    - 22.6.1. BUSINESS OVERVIEW
    - 22.6.2. PRODUCT OFFERINGS
  - 22.7. CIRCLE DNA
    - 22.7.1. BUSINESS OVERVIEW
    - 22.7.2. PRODUCT OFFERINGS
  - 22.8. DANAHER

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 22.8.1. □ BUSINESS OVERVIEW
- 22.8.2. □ PRODUCT OFFERINGS
- 22.9. □ EVERLYWELL
- 22.9.1. □ BUSINESS OVERVIEW
- 22.9.2. □ PRODUCT OFFERINGS
- 22.10. □ GE HEALTHCARE
- 22.10.1. □ BUSINESS OVERVIEW
- 22.10.2. □ PRODUCT OFFERINGS
- 22.11. □ GENEDX
- 22.11.1. □ BUSINESS OVERVIEW
- 22.11.2. □ PRODUCT OFFERINGS
- 22.12. □ GENETRACK INDIA
- 22.12.1. □ BUSINESS OVERVIEW
- 22.12.2. □ PRODUCT OFFERINGS
- 22.13. □ HELIX
- 22.13.1. □ BUSINESS OVERVIEW
- 22.13.2. □ PRODUCT OFFERINGS
- 22.14. □ GENOMIX
- 22.14.1. □ BUSINESS OVERVIEW
- 22.14.2. □ PRODUCT OFFERINGS
- 22.15. □ MAINZ BIOMED N.V.
- 22.15.1. □ BUSINESS OVERVIEW
- 22.15.2. □ PRODUCT OFFERINGS
- 22.16. □ MAPMYGENOME
- 22.16.1. □ BUSINESS OVERVIEW
- 22.16.2. □ PRODUCT OFFERINGS
- 22.17. □ MERCK KGAA
- 22.17.1. □ BUSINESS OVERVIEW
- 22.17.2. □ PRODUCT OFFERINGS
- 22.18. □ MYDNA LIFE AUSTRALIA
- 22.18.1. □ BUSINESS OVERVIEW
- 22.18.2. □ PRODUCT OFFERINGS
- 22.19. □ MYHERITAGE
- 22.19.1. □ BUSINESS OVERVIEW
- 22.19.2. □ PRODUCT OFFERINGS
- 22.20. □ NATERA
- 22.20.1. □ BUSINESS OVERVIEW
- 22.20.2. □ PRODUCT OFFERINGS
- 22.21. □ TELLMEGEN
- 22.21.1. □ BUSINESS OVERVIEW
- 22.21.2. □ PRODUCT OFFERINGS
- 22.22. □ VITAGEN-X PRECISION NUTRITION
- 22.22.1. □ BUSINESS OVERVIEW
- 22.22.2. □ PRODUCT OFFERINGS
- 23. □ REPORT SUMMARY
- 23.1. □ KEY TAKEAWAYS
- 23.2. □ STRATEGIC RECOMMENDATIONS

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

[www.scotts-international.com](http://www.scotts-international.com)

- 24. QUANTITATIVE SUMMARY
  - 24.1. MARKET BY PRODUCT TYPE
    - 24.1.1. NORTH AMERICA
    - 24.1.2. EUROPE
    - 24.1.3. APAC
    - 24.1.4. LATIN AMERICA
    - 24.1.5. MIDDLE EAST & AFRICA
  - 24.2. MARKET BY TECHNOLOGY
    - 24.2.1. NORTH AMERICA
    - 24.2.2. EUROPE
    - 24.2.3. APAC
    - 24.2.4. LATIN AMERICA
    - 24.2.5. MIDDLE EAST & AFRICA
  - 24.3. MARKET BY SAMPLE TYPE
    - 24.3.1. NORTH AMERICA
    - 24.3.2. EUROPE
    - 24.3.3. APAC
    - 24.3.4. LATIN AMERICA
    - 24.3.5. MIDDLE EAST & AFRICA
  - 24.4. MARKET BY APPLICATION
    - 24.4.1. NORTH AMERICA
    - 24.4.2. EUROPE
    - 24.4.3. APAC
    - 24.4.4. LATIN AMERICA
    - 24.4.5. MIDDLE EAST & AFRICA
  - 24.5. MARKET BY END USER
    - 24.5.1. NORTH AMERICA
    - 24.5.3. EUROPE
    - 24.5.5. APAC
    - 24.5.7. LATIN AMERICA
    - 24.5.8. MIDDLE EAST & AFRICA
- 25. APPENDIX
  - 25.1. RESEARCH METHODOLOGY
  - 25.2. RESEARCH PROCESS
  - 25.3. REPORT ASSUMPTIONS & CAVEATS
    - 25.3.1. KEY CAVEATS
    - 25.3.2. CURRENCY CONVERSION
  - 25.4. ABBREVIATIONS

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

**DNA Diagnostics Market - Global Outlook & Forecast 2025-2030**

Market Report | 2025-04-16 | 429 pages | Arizton Advisory & Intelligence

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scott's-international.com

**ORDER FORM:**

Select license	License	Price
	Single User License	\$4799.00
	Team License	\$4999.00
	Enterprisewide	\$5999.00
		VAT
		Total

\*Please circle the relevant license option. For any questions please contact support@scott's-international.com or 0048 603 394 346.

\*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-03-05"/>
		Signature	<input type="text"/>

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scott's-international.com

www.scott's-international.com